ImmunoVaccine (OTCQX:IMMVF; TSX:IMV) appointed Pierre Labbe as CFO, effective Feb. 20, to lead the company's financial strategy and operations, with an emphasis on expanding financing and business development operations as the company continues to advance its clinical program and expand its pipeline.
Mr. Labbe brings to Immunovaccine more than 15 years of experience in the role of CFO. He was an integral part of the team that negotiated the acquisition of Medicago by Mitsubishi Tanabe Pharma in 2013 for an enterprise value of $357- million.
In a statement, Frederic Ors, Immunovaccine's CEO, said Mr. Labbe’s track record includes an ideal combination of financial, operational and strategic leadership, and a proven ability to identify growth opportunities in both life sciences and technology companies.
Immunovaccine develops cancer immunotherapies and infectious disease vaccines based on its DepoVax platform, a patented delivery agent that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.